EU/3/10/758: Orphan designation for the treatment of post-polycythaemia vera myelofibrosis

Pomalidomide

Overview

Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in November 2016 on request of the Sponsor.

On 27 July 2010, orphan designation (EU/3/10/758) was granted by the European Commission to Celgene Europe Limited, United Kingdom, for pomalidomide for the treatment of post-polycythaemia vera myelofibrosis.

Key facts

Active substance
Pomalidomide
Intended use
Treatment of post-polycythaemia vera myelofibrosis
Orphan designation status
Withdrawn
EU designation number
EU/3/10/758
Date of designation
27/07/2010
Sponsor

Celgene Europe Limited
1 Longwalk Road
Stockley Park
Uxbridge
Middlesex UB11 1DB
United Kingdom
Telephone: +44 208 831 83 00
Telefax: +44 208 831 83 01
E-mail: medinfo.uk.ire@celgene.com

Review of designation

Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in November 2016 on request of the Sponsor.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating